XML 46 R35.htm IDEA: XBRL DOCUMENT
v3.22.2

Revenue (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2022
Disaggregation of Revenue [Abstract] |
Disaggregation of Revenue [Table Text Block] | The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We have revised prior periods to conform to current year presentation:
| Three Months Ended June 30, |  |
| 2022 |  | 2021 |  |  |  |
Businesses | U.S. |  | Int'l |  | Total |  | U.S. |  | Int'l |  | Total |  |  |  |  |  |  |  |
Endoscopy | $ | 338 |  |  | $ | 221 |  |  | $ | 560 |  |  | $ | 316 |  |  | $ | 235 |  |  | $ | 551 |  |  |  |  |  |  |  |  |
Urology and Pelvic Health | 320 |  |  | 130 |  |  | 450 |  |  | 285 |  |  | 112 |  |  | 397 |  |  |  |  |  |  |  |  |
Neuromodulation | 186 |  |  | 53 |  |  | 239 |  |  | 194 |  |  | 53 |  |  | 247 |  |  |  |  |  |  |  |  |
MedSurg | 844 |  |  | 404 |  |  | 1,248 |  |  | 794 |  |  | 400 |  |  | 1,195 |  |  |  |  |  |  |  |  |
Interventional Cardiology Therapies | 192 |  |  | 382 |  |  | 574 |  |  | 206 |  |  | 369 |  |  | 574 |  |  |  |  |  |  |  |  |
Watchman | 225 |  |  | 25 |  |  | 250 |  |  | 192 |  |  | 24 |  |  | 216 |  |  |  |  |  |  |  |  |
Cardiac Rhythm Management | 342 |  |  | 199 |  |  | 541 |  |  | 314 |  |  | 210 |  |  | 524 |  |  |  |  |  |  |  |  |
Electrophysiology | 73 |  |  | 79 |  |  | 152 |  |  | 34 |  |  | 62 |  |  | 95 |  |  |  |  |  |  |  |  |
Cardiology | 832 |  |  | 685 |  |  | 1,517 |  |  | 746 |  |  | 664 |  |  | 1,410 |  |  |  |  |  |  |  |  |
Peripheral Interventions | 257 |  |  | 221 |  |  | 478 |  |  | 260 |  |  | 213 |  |  | 473 |  |  |  |  |  |  |  |  |
Cardiovascular | 1,089 |  |  | 906 |  |  | 1,996 |  |  | 1,005 |  |  | 877 |  |  | 1,883 |  |  |  |  |  |  |  |  |
Total Net Sales | $ | 1,933 |  |  | $ | 1,311 |  |  | $ | 3,244 |  |  | $ | 1,800 |  |  | $ | 1,277 |  |  | $ | 3,077 |  |  |  |  |  |  |  |  |
| Six Months Ended June 30,
| 2022 |  | 2021
Businesses | U.S. |  | Int'l |  | Total |  | U.S. |  | Int'l |  | Total
Endoscopy | $ | 650 |  |  | $ | 441 |  |  | $ | 1,091 |  |  | $ | 596 |  |  | $ | 454 |  |  | $ | 1,050 |
Urology and Pelvic Health | 606 |  |  | 257 |  |  | 863 |  |  | 542 |  |  | 216 |  |  | 758 |
Neuromodulation | 346 |  |  | 101 |  |  | 448 |  |  | 345 |  |  | 99 |  |  | 444 |
MedSurg | 1,602 |  |  | 799 |  |  | 2,402 |  |  | 1,483 |  |  | 769 |  |  | 2,252 |
Interventional Cardiology Therapies | 378 |  |  | 740 |  |  | 1,118 |  |  | 400 |  |  | 699 |  |  | 1,100 |
Watchman | 428 |  |  | 48 |  |  | 476 |  |  | 341 |  |  | 45 |  |  | 386 |
Cardiac Rhythm Management | 667 |  |  | 394 |  |  | 1,061 |  |  | 590 |  |  | 403 |  |  | 993 |
Electrophysiology | 123 |  |  | 147 |  |  | 270 |  |  | 64 |  |  | 115 |  |  | 179 |
Cardiology | 1,596 |  |  | 1,329 |  |  | 2,925 |  |  | 1,395 |  |  | 1,263 |  |  | 2,658 |
Peripheral Interventions | 513 |  |  | 430 |  |  | 944 |  |  | 498 |  |  | 407 |  |  | 906 |
Cardiovascular | 2,109 |  |  | 1,760 |  |  | 3,868 |  |  | 1,893 |  |  | 1,670 |  |  | 3,564 |
Specialty Pharmaceuticals | — |  |  | — |  |  | — |  |  | 10 |  |  | 4 |  |  | 13 |
Total Net Sales | $ | 3,711 |  |  | $ | 2,559 |  |  | $ | 6,270 |  |  | $ | 3,386 |  |  | $ | 2,443 |  |  | $ | 5,829 |
Refer to Note K- Segment Reporting for information on our reportable segments.
| Three Months Ended June 30, |  | Six Months Ended June 30,
Regions | 2022 |  | 2021 |  | 2022 |  | 2021
U.S. | $ | 1,933 |  |  | $ | 1,800 |  |  | $ | 3,711 |  |  | $ | 3,376 |
Europe, Middle East and Africa | 660 |  |  | 662 |  |  | 1,284 |  |  | 1,266 |
Asia-Pacific | 530 |  |  | 520 |  |  | 1,047 |  |  | 994 |
Latin America and Canada | 120 |  |  | 95 |  |  | 228 |  |  | 180 |
Medical Devices | 3,244 |  |  | 3,077 |  |  | 6,270 |  |  | 5,816 |
U.S. | — |  |  | — |  |  | — |  |  | 10 |
International | — |  |  | — |  |  | — |  |  | 4 |
Specialty Pharmaceuticals | — |  |  | — |  |  | — |  |  | 13 |
Total Net Sales | $ | 3,244 |  |  | $ | 3,077 |  |  | $ | 6,270 |  |  | $ | 5,829 |
Emerging Markets(1) | $ | 427 |  |  | $ | 359 |  |  | $ | 817 |  |  | $ | 676 |
(1) We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently includes the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Turkey and Vietnam.

X
- References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration